Emerging Threat of Xylazine
Xylazine's rising prevalence, especially as a fentanyl adulterant, contributes to increased opioid-related morbidity and mortality. Its presence across clinical, forensic, and environmental samples underscores the urgent need for enhanced surveillance, clinician education, public awareness, and targeted policy responses.
Authors
- Marilyn A. Huestis (ORCID: https://orcid.org/0000-0003-2137-4645)
- Nicholas Nacca
- Tanzy Love (ORCID: https://orcid.org/0000-0002-7154-0229)
- Ralph Thomas Becker (ORCID: https://orcid.org/0000-0002-0789-6749)
- Kyla M. Jorgenson (ORCID: https://orcid.org/0009-0004-6780-6612)
- Brandy Young
- Alex J. Krotulski (ORCID: https://orcid.org/0000-0003-1775-1882)
- Y. Victoria Zhang (ORCID: https://orcid.org/0009-0007-7558-7589)
- Joshua Marvald
- Robert A Middleberg
Institutions
- Thomas Jefferson University (US)
- University of Rochester Medical Center (US)
- Argus International (United States) (US)
- Fredric Rieders Family Foundation (US)
- University of Rochester (US)
Publication Details
- Journal
- Clinical Chemistry
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1093/clinchem/hvaf147
- Primary Topic
- Veterinary Pharmacology and Anesthesia
- Type
- article
- Field-Weighted Citation Impact
- 0.00